Parabilis Medicines, a clinical-stage biopharmaceutical company, has priced its upsized initial public offering (IPO) at $20 per share, selling 33.5 million shares and raising approximately $670 million before expenses. Additionally, it granted underwriters a 30-day option to buy 5.025 million more shares. Concurrently, Parabilis is selling 4.17 million shares in a private placement to Regeneron Pharmaceuticals at $18 per share, expected to bring in about $75 million. The company's stock will begin trading on Nasdaq under the ticker PBLS on June 10, 2026. This capital raise supports Parabilis' development of novel medicines targeting previously undruggable proteins in human disease.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
